EP2776037A1 - Method of treating a proliferative disease - Google Patents

Method of treating a proliferative disease

Info

Publication number
EP2776037A1
EP2776037A1 EP12795175.4A EP12795175A EP2776037A1 EP 2776037 A1 EP2776037 A1 EP 2776037A1 EP 12795175 A EP12795175 A EP 12795175A EP 2776037 A1 EP2776037 A1 EP 2776037A1
Authority
EP
European Patent Office
Prior art keywords
braf
treatment
inhibitor
weeks
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12795175.4A
Other languages
German (de)
French (fr)
Other versions
EP2776037B1 (en
Inventor
Darrin Stuart
Meghna Das THAKUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of EP2776037A1 publication Critical patent/EP2776037A1/en
Application granted granted Critical
Publication of EP2776037B1 publication Critical patent/EP2776037B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a method of suppressing resistance to treatment with inhibitors of BRAF.
  • kinases associated with tumorigenesis include the receptor tyrosine kinases and the serine/threonine kinase, Raf kinase. These kinases play critical roles in signal transduction pathways that influence and regulate many cellular functions such as proliferation, differentiation, and survival.
  • Raf kinase is part of the Mitogen-Activated Protein Kinase (MAPK) signaling pathway comprising the Ras-Raf-MEK1-ERK signaling molecules.
  • MAPK Mitogen-Activated Protein Kinase
  • Raf has three distinct isoforms A-Raf, B-Raf, and C-Raf as distinguished by their ability to interact with its upstream modulator Ras.
  • An activating mutation of one of the Ras genes can be seen in about 20% of all tumors and the Ras/Raf/MEK/ERK pathway is activated in about 30% of all tumors (Bos et al., Cancer Res. 49:4682-4689, 1989; Hoshino et al., Oncogene 18:813-822, 1999).
  • Activating mutation in the kinase domain of B-Raf occurs in about 66% of melanomas, 12% of colon carcinoma and 14% of liver cancer (Davies et al., Nature 417:949-954, 2002; Yuen et al., Cancer Research 62:6451- 6455, 2002; Brose et al., Cancer Research 62:6997-7000, 2002).
  • Small molecule RAF inhibitors such as vemurafenib
  • BRAFV600E is a key driver of proliferation and survival in melanoma, as evidenced by tumor regression and prolonged survival in patients in late stage clinical trials.
  • the tumor response can be short-lived when resistance to a RAF inhibitor rapidly develops.
  • FIG. 1 Comparison of continuous and intermittent dosing of a BRAF inhibitor of formula II shows that taking away a growth advantage for the resistant cells by intermittent dosing delays or prevents the onset of resistance to the BRAF inhibitor.
  • the present invention is based on the discovery that Raf kinase resistant tumor cells are 'less fit' than tumor cells which are sensitive to the Raf kinase inhibitor and have a selective disadvantage over sensitive cells in the absence of the Raf kinase inhibitor.
  • resistance to treatment with a Raf kinase inhibitor is suppressed by administering the Raf kinase inhibitor on an intermittent dosing schedule.
  • Suppressing resistance to treatment means delaying or preventing the onset of resistance to treatment with the Raf kinase inhibitor.
  • intermittent dosing schedule means that that the B-Raf kinase inhibitor is administered for a period of time followed by a period of time wherein treatment with the B-Raf kinase inhibitor is withheld.
  • the Raf kinase inhibitor is administered daily for a period of 4 weeks followed by a period of two weeks without treatment and the cycle is repeated while the patient is treated with the Raf kinase inhibitor.
  • Vemurafenib (PLX4032) is a BRAF inhibitor which was approved by the FDA for the treatment of patients with melanoma whose tumors express the BRAF V600E mutation.
  • Vemurafenib has the following chemical structure:
  • the BRAF inhibitor is preferably a compound of formula II.
  • PD Pharmacodynamic
  • Pharmacodynamic (PD) analysis within individual tumors indicated that the RAF-MEK-ERK pathway is still suppressed in resistant tumors, although the degree and duration of suppression is less than in sensitive tumors. Furthermore, the kinetics of pathway inhibition and recovery are different between each resistant tumor.
  • Biochemical analyses indicate that serine/threonine kinases and modulation of negative feedback loops to serine/threonine kinases may be involved in resistance, as well as up-regulation of BRAF V600E expression.
  • Pharmacological evaluation of tumor response has provided insight into tumor cell populations and the evolution of resistance. Increasing the dose of drug administered to mice bearing resistant tumors leads to a significant yet transient tumor response, followed by tumor progression.
  • All resistant tumors have higher levels of p-ERK in the presence of the BRAF inhibitor compound compared to sensitive tumors and have faster recovery rates post-dose.
  • the kinetics of the recovery vary between resistant tumors.
  • BRAF resistant tumors depend on the presence of drug for growth and removal of the drug causes tumors to regress. Resistant cells are less fit then sensitive cells in the absence of compound.
  • the present invention utilizes this discovery to suppress resistance to treatment with a BRAF inhibitor by administering the BRAF inhibitor on an intermittent dosing schedule
  • the present invention includes a method of treating a proliferative disease, which comprises suppressing resistance to treatment with a BRAF kinase inhibitor by administering the BRAF kinase inhibitor on an intermittent dosing schedule.
  • the present invention includes A method of treating a proliferative disease characterized by a mutation in BRAF kinase, which comprises suppressing resistance to treatment with a BRAF inhibitor of the Formula II
  • the present invention further relates to a method of treating a proliferative disease characterized by a mutation in BRAF kinase, which comprises suppressing resistance to treatment with a BRAF inhibitor by administering the BRAF inhibitor on an intermittent dosing schedule.
  • This aspect of the invention further relates to a method wherein the BRAF mutation is a V600 mutation, such as BRAFV600E.
  • the proliferative diseases treated by the inventive method include cancer such as, but not limited to, bladder, breast, brain, head and neck, liver, biliary tract, carcinomas, acute and chronic lymphoid leukemias, acute and chronic myelogenous leukemias, chronic
  • myelomonocytic leukemias colorectal, gastric, gastrointestinal stromal, glioma, lymphomas, melanomas, multiple myeloma, myeloproliferative diseases, neuroendocrine, lung, pancreatic, ovarian, prostate, renal cell, sarcomas and thyroid, such as papillary thyroid, cancers.
  • Other proliferative diseases include mast cell leukemia, germ cell tumors, small-cell lung carcinoma, gastrointestinal stromal tumors, neuroblastoma, and osteosarcoma.
  • the proliferative disease treated by the inventive method is melanoma which is characterized by a V600 mutation, such as BRAFV600E, or colorectal cancer characterized by a V600 mutation, such as BRAFV600E.
  • the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 4 weeks followed by a period of two weeks without treatment and repeating the cycle while the patient is treated with the BRAF inhibitor or until resistance emerges.
  • additional intermittent dosing schedules include, for example, cycles of 1 one week on 1 week off, 2 weeks on 1 or 2 weeks off, 3 weeks on 1 , 2 or 3 weeks off, 4 weeks on 1 , 2, 3 or 4 weeks off, especially 4 weeks on 1 week off or 4 weeks on 2 weeks off, 5 weeks on 1 , 2 3, 4, or 5 weeks off, 6 weeks on and 1 , 2, 3, 4, 5 or 6 weeks off, and so on.
  • This invention further includes use of a BRAF inhibitor for the preparation of a medicament for the treatment of a proliferative disease whereby the BRAF inhibitor is administered on an intermittent dosing schedule.
  • a BRAF inhibitor of the Formula II for the preparation of a medicament for the treatment of a proliferative disease whereby the BRAF inhibitor of Formula II is administered on an intemittent dosing schedule
  • Hmex1906 primary human melanoma tumors are implanted at passage 3 into nude mice.
  • the mice were monitored until the implanted tumors reached 200-400mm 3 . Once this size is reached, the mice are dosed bid with 5mg/kg of a Raf inhibitor (Compound of Formula II) for 4 weeks. Some of the mice continue treatment while others are subject to an ntermittent treatment schedule of 4 weeks of treatment and 2 weeks of drug holiday..
  • the results are shown in Figure 1. Resistance emerged in all mice receiving the Compound of Formula II on a continuous basis, but there is no evidence of resistance in the mice that were subject to an intermittent dosing schedule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method of treating a patient with a serine/threonine kinase inhibitor wherein resistance to the treatment with a serine/threonine kinase inhibitor is suppressed by administering the serine/threonine kinase inhibitor on an intermittent dosing schedule.

Description

METHOD OF TREATING A PROLIFERATIVE DISEASE
SUMMARY
The present invention relates to a method of suppressing resistance to treatment with inhibitors of BRAF.
BACKGROUND
The involvement of kinases in proliferative diseases is well known. For example, kinases associated with tumorigenesis include the receptor tyrosine kinases and the serine/threonine kinase, Raf kinase. These kinases play critical roles in signal transduction pathways that influence and regulate many cellular functions such as proliferation, differentiation, and survival.
The development of therapies for the treatment of proliferative diseases remains a formidable challenge. A continuing need exists for improved therapeutic methods, particularly in view of the many variations amongst cancer cells with respect to their underlying mechanisms of growth and survival, their response to therapeutic agents, and their ability to mutate and become refractory or resistant to such agents.
Raf kinase is part of the Mitogen-Activated Protein Kinase (MAPK) signaling pathway comprising the Ras-Raf-MEK1-ERK signaling molecules. Raf has three distinct isoforms A-Raf, B-Raf, and C-Raf as distinguished by their ability to interact with its upstream modulator Ras. An activating mutation of one of the Ras genes can be seen in about 20% of all tumors and the Ras/Raf/MEK/ERK pathway is activated in about 30% of all tumors (Bos et al., Cancer Res. 49:4682-4689, 1989; Hoshino et al., Oncogene 18:813-822, 1999). Activating mutation in the kinase domain of B-Raf occurs in about 66% of melanomas, 12% of colon carcinoma and 14% of liver cancer (Davies et al., Nature 417:949-954, 2002; Yuen et al., Cancer Research 62:6451- 6455, 2002; Brose et al., Cancer Research 62:6997-7000, 2002).
Small molecule RAF inhibitors, such as vemurafenib, have demonstrated proof-of-concept that BRAFV600E is a key driver of proliferation and survival in melanoma, as evidenced by tumor regression and prolonged survival in patients in late stage clinical trials. Unfortunately, the tumor response can be short-lived when resistance to a RAF inhibitor rapidly develops.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 Comparison of continuous and intermittent dosing of a BRAF inhibitor of formula II shows that taking away a growth advantage for the resistant cells by intermittent dosing delays or prevents the onset of resistance to the BRAF inhibitor.
DETAILED DESCRIPTION
The present invention is based on the discovery that Raf kinase resistant tumor cells are 'less fit' than tumor cells which are sensitive to the Raf kinase inhibitor and have a selective disadvantage over sensitive cells in the absence of the Raf kinase inhibitor. Thus, according to the present invention resistance to treatment with a Raf kinase inhibitor is suppressed by administering the Raf kinase inhibitor on an intermittent dosing schedule.
Suppressing resistance to treatment means delaying or preventing the onset of resistance to treatment with the Raf kinase inhibitor.
In this application, intermittent dosing schedule means that that the B-Raf kinase inhibitor is administered for a period of time followed by a period of time wherein treatment with the B-Raf kinase inhibitor is withheld. For example, the Raf kinase inhibitor is administered daily for a period of 4 weeks followed by a period of two weeks without treatment and the cycle is repeated while the patient is treated with the Raf kinase inhibitor.
BRAF inhibitors and their use for treating proliferative diseases are known in the art
Vemurafenib (PLX4032) is a BRAF inhibitor which was approved by the FDA for the treatment of patients with melanoma whose tumors express the BRAF V600E mutation. Vemurafenib has the following chemical structure:
Another class of compounds that inhibits certain kinases in the APK pathway is the benzimidazolyl pyridyl ethers. US patent 7,482,367, which is here incorporate by reference in its entirety, discloses a B-RAF kinase inhibitor for formula I.
(I). Another class of compounds that inhibits certain kinases in the MAPK pathway is the pyrrazole pyrimidines. WO 2011/025927, which is here incorporate by reference in its entirety, discloses the compound of formula II as an inhibitor of BRAF kinase, particularly with the BRAFV600E mutation:
In the present method, the BRAF inhibitor is preferably a compound of formula II.
In an early passage primary human melanoma xenograft model designed to measure the emergence of resistance to a BRAF inhibitor, we have established that treatment of the xenogafts with a BRAF inhibitor on a long term continuous dosing regimen at clinically relevant doses resulted in the appearance of resistant tumors over the course of 4 to 6 weeks.
Pharmacodynamic (PD) analysis within individual tumors indicated that the RAF-MEK-ERK pathway is still suppressed in resistant tumors, although the degree and duration of suppression is less than in sensitive tumors. Furthermore, the kinetics of pathway inhibition and recovery are different between each resistant tumor. Biochemical analyses indicate that serine/threonine kinases and modulation of negative feedback loops to serine/threonine kinases may be involved in resistance, as well as up-regulation of BRAF V600E expression. Pharmacological evaluation of tumor response has provided insight into tumor cell populations and the evolution of resistance. Increasing the dose of drug administered to mice bearing resistant tumors leads to a significant yet transient tumor response, followed by tumor progression. Taken together with the PD data, it is reasonable to conclude that there is a great deal of tumor cell heterogeneity, and that tumors are able to rapidly adapt to the selective pressure being applied by administration of the drug . Further support for this conclusion was obtained by suspending drug treatment from mice implanted with resistant tumors. Upon drug withdrawal, tumors initially regressed for several days to weeks, followed by re-growth. These data indicate that the adaptation which occurs within a tumor cell population under selective pressure make the cells less fit in the absence of drug.
All resistant tumors have higher levels of p-ERK in the presence of the BRAF inhibitor compound compared to sensitive tumors and have faster recovery rates post-dose. The kinetics of the recovery vary between resistant tumors. BRAF resistant tumors depend on the presence of drug for growth and removal of the drug causes tumors to regress. Resistant cells are less fit then sensitive cells in the absence of compound. The present invention utilizes this discovery to suppress resistance to treatment with a BRAF inhibitor by administering the BRAF inhibitor on an intermittent dosing schedule
Thus, the present invention includes a method of treating a proliferative disease, which comprises suppressing resistance to treatment with a BRAF kinase inhibitor by administering the BRAF kinase inhibitor on an intermittent dosing schedule.
In particular, the present invention includes A method of treating a proliferative disease characterized by a mutation in BRAF kinase, which comprises suppressing resistance to treatment with a BRAF inhibitor of the Formula II
by administering the BRAF inhibitor of Formula II on an intermittent dosing schedule.
In a preferred embodiment, the present invention further relates to a method of treating a proliferative disease characterized by a mutation in BRAF kinase, which comprises suppressing resistance to treatment with a BRAF inhibitor by administering the BRAF inhibitor on an intermittent dosing schedule.
This aspect of the invention further relates to a method wherein the BRAF mutation is a V600 mutation, such as BRAFV600E. The proliferative diseases treated by the inventive method include cancer such as, but not limited to, bladder, breast, brain, head and neck, liver, biliary tract, carcinomas, acute and chronic lymphoid leukemias, acute and chronic myelogenous leukemias, chronic
myelomonocytic leukemias, colorectal, gastric, gastrointestinal stromal, glioma, lymphomas, melanomas, multiple myeloma, myeloproliferative diseases, neuroendocrine, lung, pancreatic, ovarian, prostate, renal cell, sarcomas and thyroid, such as papillary thyroid, cancers. Other proliferative diseases include mast cell leukemia, germ cell tumors, small-cell lung carcinoma, gastrointestinal stromal tumors, neuroblastoma, and osteosarcoma.
More particularly, the proliferative disease treated by the inventive method is melanoma which is characterized by a V600 mutation, such as BRAFV600E, or colorectal cancer characterized by a V600 mutation, such as BRAFV600E.
In an important aspect, the intermittent dosing schedule comprises administering the BRAF inhibitor for a period of 4 weeks followed by a period of two weeks without treatment and repeating the cycle while the patient is treated with the BRAF inhibitor or until resistance emerges. However, additional intermittent dosing schedules include, for example, cycles of 1 one week on 1 week off, 2 weeks on 1 or 2 weeks off, 3 weeks on 1 , 2 or 3 weeks off, 4 weeks on 1 , 2, 3 or 4 weeks off, especially 4 weeks on 1 week off or 4 weeks on 2 weeks off, 5 weeks on 1 , 2 3, 4, or 5 weeks off, 6 weeks on and 1 , 2, 3, 4, 5 or 6 weeks off, and so on.
This invention further includes use of a BRAF inhibitor for the preparation of a medicament for the treatment of a proliferative disease whereby the BRAF inhibitor is administered on an intermittent dosing schedule. In particular, use of a BRAF inhibitor of the Formula II for the preparation of a medicament for the treatment of a proliferative disease whereby the BRAF inhibitor of Formula II is administered on an intemittent dosing schedule
The following Example illustrates the present invention.
Example 1
Hmex1906 primary human melanoma tumors are implanted at passage 3 into nude mice. The mice were monitored until the implanted tumors reached 200-400mm3. Once this size is reached, the mice are dosed bid with 5mg/kg of a Raf inhibitor (Compound of Formula II) for 4 weeks. Some of the mice continue treatment while others are subject to an ntermittent treatment schedule of 4 weeks of treatment and 2 weeks of drug holiday.. The results are shown in Figure 1. Resistance emerged in all mice receiving the Compound of Formula II on a continuous basis, but there is no evidence of resistance in the mice that were subject to an intermittent dosing schedule.

Claims

We claim:
1. A method of treating a proliferative disease characterized by a mutation in BRAF kinase, which comprises suppressing resistance to treatment with a BRAF inhibitor of the Formula II
by administering the BRAF inhibitor of Formula II on an intermittent dosing schedule.
2. A method of claim 1 wherein the BRAF mutation is a V600 mutation.
3. A method of claim 1 wherein the proliferative disease is melanoma which is characterized by a V600 mutation or colorectal cancer characterized by a V600 mutation.
4. A method of claim 1 wherein the proliferative disease is melanoma which is characterized by BRAFV600E or colorectal cancer characterized by BRAFV600E.
5. Use of a BRAF inhibitor of Formula II
for the preparation of a medicament for the treatment of a proliferative disease whereby the BRAF inhibitor is administered on an intemittent dosing schedule.
EP12795175.4A 2011-11-11 2012-11-09 Method of treating a proliferative disease Active EP2776037B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (2)

Publication Number Publication Date
EP2776037A1 true EP2776037A1 (en) 2014-09-17
EP2776037B1 EP2776037B1 (en) 2019-01-09

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12795175.4A Active EP2776037B1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Country Status (10)

Country Link
US (1) US11007194B2 (en)
EP (1) EP2776037B1 (en)
JP (1) JP6150813B2 (en)
CN (2) CN103917236A (en)
AU (1) AU2012335663B2 (en)
BR (1) BR112014011223A8 (en)
CA (1) CA2855243C (en)
MX (1) MX354725B (en)
RU (1) RU2622015C2 (en)
WO (1) WO2013070996A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
JP6342396B2 (en) * 2012-08-07 2018-06-13 ノバルティス アーゲー Combination medicine comprising B-Raf inhibitor, EGFR inhibitor and optionally PI3K-α inhibitor
FI3463345T3 (en) * 2016-06-03 2023-01-31 Pharmaceutical combinations
WO2018107146A1 (en) * 2016-12-11 2018-06-14 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of braf mutant cancers
WO2020011141A1 (en) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 Diarylpyrazole compound, composition comprising same, and use thereof
TWI817018B (en) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 Compounds for the treatment of braf-associated diseases and disorders
WO2021142026A1 (en) * 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
TW202426436A (en) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 Compounds for the treatment of braf-associated diseases and disorders
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
US12357645B2 (en) 2023-03-09 2025-07-15 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (en) 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU754830C (en) 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (en) 1999-01-13 2011-02-10 Bayer Corp ?-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
US20050043409A1 (en) 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
ATE374753T1 (en) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE
US20080085902A1 (en) 2003-09-23 2008-04-10 Guido Bold Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
MXPA06007820A (en) 2004-01-09 2006-09-01 Novartis Ag Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors.
RU2401265C2 (en) 2004-06-10 2010-10-10 Айрм Ллк Compounds and compositions as protein kinase inhibitors
EP1871773A1 (en) 2005-03-17 2008-01-02 Novartis AG N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
US7608635B2 (en) 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
EP1919460A2 (en) 2005-08-22 2008-05-14 Novartis AG Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TWI387592B (en) 2005-08-30 2013-03-01 Novartis Ag Substituted benzimidazoles and methods of their use as inhibitors of kinases associated with tumorigenesis
WO2007105058A2 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
KR20080108516A (en) 2006-04-05 2008-12-15 노파르티스 아게 Combination of Therapeutics to Treat Cancer
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CN103739595A (en) 2006-10-02 2014-04-23 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
JP2010505859A (en) 2006-10-06 2010-02-25 アイアールエム・リミテッド・ライアビリティ・カンパニー Protein kinase inhibitors and methods for using the same
US20100069458A1 (en) 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
WO2009016460A2 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
UA100865C2 (en) 2007-10-19 2013-02-11 Эбботт Гмбх Унд Ко. Кг Normal;heading 1;heading 2;heading 3;SOLID DISPERSION PRODUCT OF N-ARYL UREA-BASED DRUGS
CN101861316B (en) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of the MGLUR2 receptor
WO2009115572A2 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PT2324008E (en) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarylpyrazoles as protein kinase inhibitors
CN102123987A (en) 2008-07-28 2011-07-13 吉里德科学公司 Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
ES2422263T3 (en) 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (en) 2009-01-29 2011-03-16 Novartis Ag SOLID ORAL FORMULATIONS OF A PYRIDOID-PYRIMIDINONE
RU2402602C1 (en) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН CELL LINE OF HUMAN MELANOMA mel Rac, APPLIED FOR OBTAINING ANTITUMOUR VACCINE
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (en) 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
US8546413B2 (en) 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (en) 2009-08-20 2013-04-18 한국과학기술연구원 1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN104958294A (en) 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 Sulfonamido derivatives of 3, 4-diarylpyrazoles as protein kinase inhibitors
CN102918034B (en) 2010-03-30 2015-06-03 维颂公司 Polysubstituted aromatic compounds as inhibitors of thrombin
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
CA2829263C (en) 2011-03-21 2020-05-12 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
PH12013502523A1 (en) 2011-06-14 2019-10-11 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
SI2782557T1 (en) 2011-11-23 2019-02-28 Array Biopharma, Inc., Pharmaceutical formulations
JP2015536964A (en) 2012-11-08 2015-12-24 ノバルティス アーゲー Pharmaceutical combinations comprising B-RAF inhibitors and histone deacetylase inhibitors and their use in the treatment of proliferative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013070996A1 *

Also Published As

Publication number Publication date
JP2014533272A (en) 2014-12-11
CA2855243A1 (en) 2013-05-16
RU2014117707A (en) 2015-12-20
BR112014011223A2 (en) 2017-05-09
JP6150813B2 (en) 2017-06-21
BR112014011223A8 (en) 2023-01-31
EP2776037B1 (en) 2019-01-09
AU2012335663B2 (en) 2015-12-24
WO2013070996A1 (en) 2013-05-16
US11007194B2 (en) 2021-05-18
AU2012335663A1 (en) 2014-05-29
MX354725B (en) 2018-03-16
US20140275136A1 (en) 2014-09-18
CN108542906A (en) 2018-09-18
HK1198920A1 (en) 2015-06-19
RU2622015C2 (en) 2017-06-08
MX2014005726A (en) 2014-05-28
CA2855243C (en) 2020-04-14
CN103917236A (en) 2014-07-09

Similar Documents

Publication Publication Date Title
EP2776037B1 (en) Method of treating a proliferative disease
Furukawa Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
Alzahrani PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Martinelli et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells
von Euw et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
Strumberg et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Tanaka et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations
Petrulea et al. PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma
Patyna et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Luke et al. The biology and clinical development of MEK inhibitors for cancer
Thompson et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts
Stein et al. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma
Girotti et al. Deja Vu: EGF receptors drive resistance to BRAF inhibitors
Evans et al. Current and future trials of targeted therapies in cutaneous melanoma
Yi et al. Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer
Li et al. Combination of anti-EGFR and anti-VEGF drugs for the treatment of previously treated metastatic colorectal cancer: a case report and literature review
Schmid et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma
Imyanitov et al. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation
Ding et al. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2
HK1198920B (en) Method of treating a proliferative disease
Czejka et al. Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer
Mallucci et al. The end of KRAS, and other, cancers? A new way forward
Woessner et al. ARRY-162, a potent and selective MEK 1/2 inhibitor, shows enhanced efficacy in combination with other targeted kinase inhibitors and with chemotherapy
Brown et al. Novel approaches in the treatment of thyroid cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150309

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198920

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180703

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1086461

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012055767

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190109

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1086461

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190509

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190409

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ARRAY BIOPHARMA INC.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190410

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190509

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190409

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: ARRAY BIOPHARMA INC., US

Free format text: FORMER OWNER: NOVARTIS AG, CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012055767

Country of ref document: DE

Representative=s name: D YOUNG & CO LLP, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012055767

Country of ref document: DE

Owner name: ARRAY BIOPHARMA INC., BOULDER, US

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012055767

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20191107 AND 20191113

26N No opposition filed

Effective date: 20191010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG INHABER

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20121109

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190109

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230506

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20251014

Year of fee payment: 14

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251201

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251013

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251009

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251013

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251201

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20251013

Year of fee payment: 14